University Hospitals Harrington Heart & Vascular Institute Co-Leads National Trial of PE Solution

Innovations in Cardiovascular Medicine & Surgery | May 2025

A next-generation solution for treating pulmonary embolism (PE) appears to be safe and effective, according to an article recently published in JSCAI: Journal of the Society of Cardiovascular Angiography and Interventions.

Jun Li, MD

Jun Li, MD, Co-Director of the Vascular Center at University Hospitals Harrington Heart & Vascular Institute and national co-principal investigator of the AVENTUS trial, presented results on the AVENTUS thrombectomy system during the recent Society of Cardiovascular Angiography and Interventions Scientific Sessions in Washington, D.C. The AVENTUS system allows for percutaneous mechanical aspiration thrombectomy with autologous blood reinfusion.

Trial results showed that among 120 patients with acute, intermediate-risk PE with symptoms for less than two weeks, clot burden declined by 35.9% and no patients required a blood transfusion. In addition, there were no device-related major events occurring in the first 48 hours after the procedure. At 30 days, patients increased walking distance and reported fewer symptoms.

“This study confirms that thrombectomy and autologous blood reinfusion with the AVENTUS Thrombectomy System is a safe and effective primary treatment option in patients with acute intermediate-risk PE to improve RV function and reduce clot burden with minimal blood loss,” Dr. Li and her colleagues write in JSCAI.